In February we had the Editas (EDIT) IPO which doubled promptly in the market. The entire biotechnology world is enamored with the potential of these core gene-editing technologies.
One of the companies mentioned in our note: A CRISPR view of Editas was Intellia so their offering has been much anticipated.
Here's our brief note on NTLA:
Bullets and Tickers
- Another play on the CRISPR/CaS9 gene-editing technology.
- Two major collaborations – one with Novartis and the other with Regeneron. Circa $500M in potential milestone payments and circa 10% royalties.